Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience DOI
Viviane Liao, Leore Lavin,

Michael M Ong

et al.

The Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 16, 2025

ABSTRACT The JAK/STAT pathway is implicated in the pathogenesis of cutaneous T‐cell lymphoma (CTCL), with early studies suggesting that JAK inhibitors (JAKi) may be used for treating CTCL. Patients CTCL have other indications JAKi use, but data on agents limited due to warnings against their use malignancy. We retrospectively characterized experience our tertiary cancer center patients seen between years 2011 and 2024. identified 26 who received a JAKi: 7 prior diagnosis (topical ( n = 5) or oral 2) itchy rash eczema), 6 as treatment, 13 following (oral ruxolitinib graft versus host disease (GvHD) allogeneic stem cell transplant 9), hemophagocytic lymphohistiocytosis 3), topical alopecia areata 1)). Of six treated JAKi, four two ruxolitinib. One patient orally has had complete response 3 another diminishing lesion size 1 year. topically skin‐limited demonstrated plaque thinning. nine GvHD, five experienced relapse median 8 weeks exposure. This study provides initial insights into real‐world Further studies, however, are required characterize any association development, well safety context pre‐existing

Language: Английский

Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience DOI
Viviane Liao, Leore Lavin,

Michael M Ong

et al.

The Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 16, 2025

ABSTRACT The JAK/STAT pathway is implicated in the pathogenesis of cutaneous T‐cell lymphoma (CTCL), with early studies suggesting that JAK inhibitors (JAKi) may be used for treating CTCL. Patients CTCL have other indications JAKi use, but data on agents limited due to warnings against their use malignancy. We retrospectively characterized experience our tertiary cancer center patients seen between years 2011 and 2024. identified 26 who received a JAKi: 7 prior diagnosis (topical ( n = 5) or oral 2) itchy rash eczema), 6 as treatment, 13 following (oral ruxolitinib graft versus host disease (GvHD) allogeneic stem cell transplant 9), hemophagocytic lymphohistiocytosis 3), topical alopecia areata 1)). Of six treated JAKi, four two ruxolitinib. One patient orally has had complete response 3 another diminishing lesion size 1 year. topically skin‐limited demonstrated plaque thinning. nine GvHD, five experienced relapse median 8 weeks exposure. This study provides initial insights into real‐world Further studies, however, are required characterize any association development, well safety context pre‐existing

Language: Английский

Citations

0